Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure

Description

Autophagy is considered an important component of Heart failure progression. Deubiquitination enzymes play an important role in autophagy. An important regulatory process within the autophagy pathway is ubiquitination. Ubiquitination targets proteins for degradation. On the contrary, de-ubiquitinating proteins (such as UCHL1) reverses this process. Studies have demonstrated deubiquitination to be linked to certain pathological processes, such as heart failure. UCHL1 will be examined as a potential marker of disease progression in acute decompensated heart failure.

Conditions

Heart Failure, Dyspnea; Cardiac

Talk to us

Study Overview

On this page

Study Details

Study overview

Autophagy is considered an important component of Heart failure progression. Deubiquitination enzymes play an important role in autophagy. An important regulatory process within the autophagy pathway is ubiquitination. Ubiquitination targets proteins for degradation. On the contrary, de-ubiquitinating proteins (such as UCHL1) reverses this process. Studies have demonstrated deubiquitination to be linked to certain pathological processes, such as heart failure. UCHL1 will be examined as a potential marker of disease progression in acute decompensated heart failure.

To Explore the Potential of UCH-L1 as a Novel Therapeutic and Diagnostic Target in Heart Failure

Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Columbia

Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC, Columbia, South Carolina, United States, 29209-1638

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Admission for decompensated HF (traditional diagnostic criteria will be utilized for diagnosing ADHF - presence of dyspnea as presenting complaint; evidence of volume overload - peripheral or pulmonary edema, elevated jugular venous pressure \> 10 cmH2O, presence of hepatojugular reflux, or ascites; elevated B-type Natriuretic Peptide (\>100ng/ml); evidence of pulmonary vascular congestion on chest x-ray1, or Admission for dyspnea that is NOT related to ADHF (absence of all HF symptoms and signs mentioned in ADHF inclusion criteria- except for dyspnea as presenting complaint)
  • * Able to give informed consent
  • * Age \>= 18 years
  • * Mortality during inpatient observation
  • * Presence of acute stroke (ischemic or hemorrhagic)
  • * Presence of intracranial hemorrhage
  • * History of acute stroke (ischemic or hemorrhagic) or intracranial hemorrhage within the preceding 6 months
  • * Presence of decompensated liver disease (elevated ALT/AST; ascites; Acute variceal bleeding; or hepatic encephalopathy)
  • * Presence of sepsis
  • * Presence of severe hyponatremia (Serum sodium \< 130 meq/L)
  • * Active malignancy (undergoing chemotherapy, radiation therapy, or planned surgical intervention)
  • * SARS-CoV-2 positive during the current admission

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

VA Office of Research and Development,

Taixing Cui, PhD MB, PRINCIPAL_INVESTIGATOR, Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC

Study Record Dates

2025-04-01